Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HRH1 | P35367 | 1/20 | 0.37 |
| ▸ | PPARD | Q03181 | 1/20 | 0.35 |
| ▸ | APP | P05067 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | HMOX1 | P09601 | 1/20 | 0.35 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12823853 | 0.96 | MEN1 (0.43) | MEN1KMT2APTGS2FFAR1FFAR4 | |
| SCHEMBL12823077 | 0.91 | ESR1 (0.39) | MEN1KMT2AFFAR1APPCYP2C19 | |
| SCHEMBL10303194 | 0.90 | FFAR1 (0.39) | MEN1KMT2APTGS2FFAR1FFAR4 | |
| SCHEMBL12822069 | 0.89 | FFAR1 (0.35) | MEN1KMT2APTGS2FFAR1FFAR4 | |
| SCHEMBL13586553 | 0.89 | MEN1 (0.41) | MEN1KMT2AFFAR1FFAR4DRD2 | |
| SCHEMBL13586138 | 0.89 | PTGS2 (0.44) | PTGS2FFAR1FFAR4PPARDAPP | |
| SCHEMBL12822962 | 0.88 | PTGS2 (0.39) | MEN1KMT2APTGS2FFAR1FFAR4 | |
| SCHEMBL12823072 | 0.88 | S1PR1 (0.33) | MEN1KMT2APTGS2FFAR1FFAR4 | |
| SCHEMBL14766204 | 0.87 | FFAR1 (0.43) | MEN1KMT2APTGS2FFAR1FFAR4 | |
| SCHEMBL12823817 | 0.86 | ESR1 (0.40) | MEN1KMT2AFFAR1APPCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2011-04-21 | — | — | US | disclosed |
| WO-2009150966-A1 | TETRACYCLIC LIQUID CRYSTALLINE COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY ELEMENT | チッソ株式会社 (JP) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | LEF1, LAS1L, EFHD2 | MEN1 2496/4885KMT2A 1271/4885PTGS2 3919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.